Rose Daniel M, Marshall Richard, Surber Mark W
Pulmonary Fibrosis Foundation, Chicago, Illinois.
Respirology. 2015 Feb;20(2):185-91. doi: 10.1111/resp.12458. Epub 2015 Jan 8.
Biological complexity and the need for highly differentiated medicines means that drug discovery and development have become increasingly challenging and expensive. Thus, new paradigms for research and drug development need to be created that bring together a wide array of expertise. One potential solution is collaboration between bio-pharma and academic research centres. Two examples are discussed, one with a large pharma company (GlaxoSmithKline) and the other a small biotech (Genoa Pharmaceuticals). Patient advocacy organization can also have role in assisting in the creation of these partnerships by informing patients of ongoing research and clinical trials, and supporting the development of networks that can provide major benefit for both basic research and drug development. A major 'hurdle' for the creation of these relationships is the issue of intellectual property. Examples are provided of how this issue can be resolved.
生物复杂性以及对高度差异化药物的需求意味着药物研发变得越来越具有挑战性且成本高昂。因此，需要创建新的研究和药物开发范式，将广泛的专业知识汇聚在一起。一个潜在的解决方案是生物制药公司与学术研究中心之间的合作。文中讨论了两个例子，一个是与大型制药公司（葛兰素史克）的合作，另一个是与小型生物技术公司（热那亚制药公司）的合作。患者权益倡导组织在协助建立这些伙伴关系方面也可以发挥作用，通过向患者通报正在进行的研究和临床试验，并支持能够为基础研究和药物开发带来重大益处的网络发展。建立这些关系的一个主要“障碍”是知识产权问题。文中提供了该问题如何得以解决的例子。
